| Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial SP Buchbinder, DV Mehrotra, A Duerr, DW Fitzgerald, R Mogg, D Li, ... The Lancet 372 (9653), 1881-1893, 2008 | 1988 | 2008 |
| HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis MJ McElrath, SC De Rosa, Z Moodie, S Dubey, L Kierstead, H Janes, ... The Lancet 372 (9653), 1894-1905, 2008 | 876 | 2008 |
| Safety and Immunogenicity of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B gag/pol/nef Vaccine in Healthy Adults FH Priddy, D Brown, J Kublin, K Monahan, DP Wright, J Lalezari, ... Clinical infectious diseases 46 (11), 1769-1781, 2008 | 322 | 2008 |
| Step Study Protocol Team. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial SP Buchbinder, DV Mehrotra, A Duerr, DW Fitzgerald, R Mogg, D Li, ... Lancet 372 (9653), 1881-1893, 2008 | 306 | 2008 |
| Should baseline be a covariate or dependent variable in analyses of change from baseline in clinical trials? GF Liu, K Lu, R Mogg, M Mallick, DV Mehrotra Statistics in medicine 28 (20), 2509-2530, 2009 | 217 | 2009 |
| Scientific white paper on concentration-QTc modeling C Garnett, PL Bonate, Q Dang, G Ferber, D Huang, J Liu, D Mehrotra, ... Journal of Pharmacokinetics and Pharmacodynamics 45, 383-397, 2018 | 168 | 2018 |
| Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and … BJ Crowe, HA Xia, JA Berlin, DJ Watson, H Shi, SL Lin, J Kuebler, ... Clinical Trials 6 (5), 430-440, 2009 | 146 | 2009 |
| Use of the false discovery rate for evaluating clinical safety data DV Mehrotra, JF Heyse Statistical methods in medical research 13 (3), 227-238, 2004 | 143 | 2004 |
| A cautionary note on exact unconditional inference for a difference between two independent binomial proportions DV Mehrotra, ISF Chan, RL Berger Biometrics 59 (2), 441-450, 2003 | 139 | 2003 |
| AIDS clinical trials group 5197: a placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV … RT Schooley, J Spritzler, H Wang, MM Lederman, D Havlir, DR Kuritzkes, ... The Journal of infectious diseases 202 (5), 705-716, 2010 | 132 | 2010 |
| Clinical endpoints for evaluating efficacy in COVID-19 vaccine trials DV Mehrotra, HE Janes, TR Fleming, PW Annunziato, KM Neuzil, ... Annals of internal medicine 174 (2), 221-228, 2021 | 116 | 2021 |
| Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay S Dubey, J Clair, TM Fu, L Guan, R Long, R Mogg, K Anderson, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 45 (1), 20-27, 2007 | 105 | 2007 |
| Cross-reactivity of anti–HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1–positive individuals from 4 continents PM Coplan, SB Gupta, SA Dubey, P Pitisuttithum, A Nikas, B Mbewe, ... The Journal of infectious diseases 191 (9), 1427-1434, 2005 | 104 | 2005 |
| Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study) RV Barnabas, JN Wasserheit, Y Huang, H Janes, R Morrow, J Fuchs, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 57 (3), 238-244, 2011 | 102 | 2011 |
| An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1–infected male subjects: Results from a randomized placebo … DW Fitzgerald, H Janes, M Robertson, R Coombs, I Frank, P Gilbert, ... Journal of Infectious Diseases 203 (6), 765-772, 2011 | 89 | 2011 |
| Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC LS Kierstead, S Dubey, B Meyer, TW Tobery, R Mogg, VR Fernandez, ... AIDS research and human retroviruses 23 (1), 86-92, 2007 | 88 | 2007 |
| Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B gag Vaccines in Healthy Adults CD Harro, MN Robertson, MA Lally, LD O'Neill, S Edupuganti, ... AIDS research and human retroviruses 25 (1), 103-114, 2009 | 80 | 2009 |
| Effects of controlled-onset extended-release verapamil on nocturnal blood pressure (dippers versus nondippers) WB White, DV Mehrotra, HR Black, TD Fakouhi The American journal of cardiology 80 (4), 469-474, 1997 | 80 | 1997 |
| Estimating the benefit of an HIV-1 vaccine that reduces viral load set point SB Gupta, LP Jacobson, JB Margolick, CR Rinaldo, JP Phair, ... The Journal of infectious diseases 195 (4), 546-550, 2007 | 79 | 2007 |
| Improving the Brown-Forsythe solution to the generalized Behrens-Fisher problem DV Mehrotra Communications in Statistics-Simulation and Computation 26 (3), 1139-1145, 1997 | 69 | 1997 |
